APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese

被引:32
|
作者
Chien, Kuo-Liong [2 ]
Fang, Woei-Horng [1 ]
Wen, Hui-Chin [1 ]
Lin, Hsing-Pei [1 ]
Lin, Yen-Lin [1 ]
Lin, Shu-Wha [1 ]
Wu, June-Hsieh
Kao, Jau-Tsuen [1 ,3 ]
机构
[1] Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Publ Sch, Inst Prevent Med, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan
关键词
apolipoprotein A1/C3/A5; triglyceride; HDL cholesterol; haplotype;
D O I
10.1016/j.cca.2007.12.014
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Apolipoprotein A5 gene (APOA5) has been shown to modulate plasma triglyceride concentrations. We investigated 2 distinct APOA1/C3/A5 haplotypes roles for hypertriglyceridemia. Methods: We recruited 308 cases of hypertriglyceridemia and 281 normal controls from a hospital. Twelve single nucleotide polymorphisms (SNPs) across the APOA1/C3/A5 gene region were genotyped. Results: One haplotype containing the minor alleles of the APOA5 (-1131T>C, c.553G>T) and APOA1 (-3013C>T,-75G>A) was more prevalent in cases than in controls (11.3% vs. 1.1%, respectively) and was statistically significantly associated with high triglycerides (adjusted odds ratio: 12.83, 95% confidence interval [CI]: 5.1-32.4, P<0.001). Another haplotype that was associated with hypertriglyceridemia (adjusted odds ratio 2.13, 95% CI, 1.37-3.29, P=0.001). Participants carrying both minor alleles of APOA5-1131CC and c.553TT had a 116% higher triglyceride concentration compared with those carrying common allele. Conclusions: The APOA1/C3/A5 haplotype represents an important locus for predicting risk of hypertriglyceridemia among Taiwanese. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:56 / 62
页数:7
相关论文
共 50 条
  • [31] Apolipoprotein A1/C3/A5 haplotypes and serum lipid levels
    Yin, Rui-Xing
    Li, Yi-Yang
    Lai, Chao-Qiang
    LIPIDS IN HEALTH AND DISEASE, 2011, 10
  • [32] Apolipoprotein A1/C3/A5 haplotypes and serum lipid levels
    Rui-Xing Yin
    Yi-Yang Li
    Chao-Qiang Lai
    Lipids in Health and Disease, 10
  • [33] APOA5 and APOA1 polymorphisms are associated with triglyceride levels in Mexican children
    Suarez-Sanchez, F.
    Klunder-Klunder, M.
    Valladares-Salgado, A.
    Gomez-Zamudio, J.
    Peralta-Romero, J.
    Meyre, D.
    Burguete-Garcia, A.
    Cruz, M.
    PEDIATRIC OBESITY, 2017, 12 (04): : 330 - 336
  • [34] Functional polymorphisms of the APOA1/C3/A4/A5-ZPR1-BUD13 gene cluster are associated with dyslipidemia in a sex-specific pattern
    Bai, Wei
    Kou, Changgui
    Zhang, Lili
    You, Yueyue
    Yu, Weiying
    Hua, Wanqing
    Li, Yuanyuan
    Yu, Yaqin
    Zhao, Tiancheng
    Wu, Yanhua
    PEERJ, 2019, 6
  • [35] The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment
    Andrikoula, M.
    McDowell, I. F. W.
    DIABETES OBESITY & METABOLISM, 2008, 10 (04): : 271 - 278
  • [36] 载脂蛋白A5、载脂蛋白C3及载脂蛋白A5/C3比值与冠心病的关系
    吴美美
    王虹
    肖双
    孙雪
    韩婷婷
    临床荟萃, 2020, 35 (04) : 312 - 316
  • [37] Genetic determinants of plasma lipid response to dietary intervention:: the role of the APOA1/C3/A4 gene cluster and the APOE gene
    Ordovas, JM
    Schaefer, EJ
    BRITISH JOURNAL OF NUTRITION, 2000, 83 : S127 - S136
  • [38] A high-risk haplotype in the APOA1-C3-A4 gene cluster associated with myocardial infarction
    Ruiz-Narvaez, E
    Yang, YD
    Campos, H
    CIRCULATION, 2003, 108 (17) : 772 - 772
  • [39] Association of APOA1 and APOA5 polymorphisms and haplotypes with lipid parameters in a Brazilian elderly cohort
    Furuya, T. K.
    Chen, E. S.
    Ota, V. K.
    Mazzotti, D. R.
    Ramos, L. R.
    Cendoroglo, M. S.
    Araujo, L. Q.
    Burbano, R. R.
    Smith, M. A. C.
    GENETICS AND MOLECULAR RESEARCH, 2013, 12 (03): : 3495 - 3499
  • [40] ApoB x LDL-C/ApoA1 x HDL-C: A new predictor of coronary risk
    Izar, M. C. O.
    Pinto, L. D. E. S. A.
    Lopes, I. E. L.
    Fischer, S. C. P. M.
    Fonseca, M. I. H.
    Lhara, S. S. M.
    Kasinski, N.
    Fonseca, F. A. H.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (03) : 23 - 23